Yifan Pharmaceutical Co., Ltd.

Yifan Pharmaceutical Co., Ltd. saw a significant increase in its stock price today, contrasting with the modest rise of the China Shanghai Composite. However, the company has faced challenges over the past year, including a notable decline in stock value and low profitability metrics, despite being net-debt-free.

Yifan Pharmaceutical Co., Ltd. faced a significant stock decline, contrasting with the modest gain of the China Shanghai Composite. The company has seen substantial decreases in stock performance over various time frames, alongside financial challenges such as low returns and a notable drop in net profit.

Yifan Pharmaceutical Co., Ltd. saw a significant rise in its stock today, contrasting with the broader market's performance. However, the company faces challenges, including a year-long decline in stock value and decreasing net sales and operating profit. Despite being net-debt-free, its return on equity remains low.

Yifan Pharmaceutical Co., Ltd. saw a significant rise in its stock today, contrasting with the modest gain of the China Shanghai Composite index. Despite recent declines over the week and month, the company has achieved an annual return of 11.68%. It operates in the Pharmaceuticals & Biotechnology sector with a market cap of CNY 10,240 million.

Yifan Pharmaceutical Co., Ltd. saw a notable increase in its stock today, contrasting with the broader market's performance. While the company has shown resilience with positive results over the last five quarters, its long-term growth metrics reveal challenges, including declining net sales and low return on capital employed.

Yifan Pharmaceutical Co., Ltd. saw a notable decline in its stock today, dropping significantly compared to the broader market. Over the past week, the stock has decreased substantially, while its annual performance remains modest. Financial metrics reveal challenges, including low returns and declining net sales over five years.

Yifan Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. While the company has experienced a monthly increase, its one-year performance lags behind the index. Financial metrics reveal challenges, including low returns and declining net sales over the past five years.

Yifan Pharmaceutical Co., Ltd. has seen a notable increase in its stock performance, with significant gains over the past week and month. Despite challenges in long-term growth and declining net sales, the company has reported positive results for the last five quarters, highlighting strong operating cash flow.

Yifan Pharmaceutical Co., Ltd. saw a notable intraday increase on March 10, 2026, outperforming the China Shanghai Composite. While the company has shown recent short-term gains and positive quarterly results, long-term growth metrics reveal challenges, including declining net sales and operating profit, alongside concerns about financial leverage.

Yifan Pharmaceutical Co., Ltd. has recently experienced a score adjustment due to changes in its technical indicators. The company faces challenges with a low Return on Capital Employed and declining net sales, yet it has reported positive operating cash flow for the last five quarters and maintains a notable dividend yield.

Yifan Pharmaceutical Co., Ltd. has seen a notable increase in its stock performance, gaining 5.82% on February 26, 2026, and achieving an intraday high of CNY 13.62. The company has reported positive results for five consecutive quarters, with strong operating cash flow and a significant market capitalization.